AR065529A1 - Forma de dosificacion que comprende 1-{6-((3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi)-3-piridinil}-2-pirrolidinona , metodo para producirla su uso para preparar un medicamento y disolucion o suspension correspondiente - Google Patents
Forma de dosificacion que comprende 1-{6-((3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi)-3-piridinil}-2-pirrolidinona , metodo para producirla su uso para preparar un medicamento y disolucion o suspension correspondienteInfo
- Publication number
- AR065529A1 AR065529A1 ARP080100842A ARP080100842A AR065529A1 AR 065529 A1 AR065529 A1 AR 065529A1 AR P080100842 A ARP080100842 A AR P080100842A AR P080100842 A ARP080100842 A AR P080100842A AR 065529 A1 AR065529 A1 AR 065529A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- benzazepin
- stabilizer
- pyrrolidinone
- pyridinyl
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 8
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- 238000004090 dissolution Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- 239000003381 stabilizer Substances 0.000 abstract 5
- YFRBKEVUUCQYOW-UHFFFAOYSA-N 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=N1)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 YFRBKEVUUCQYOW-UHFFFAOYSA-N 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 1- {6 - [(3-cyclobutyl-2,3 , 4,5-tetrahydro-1H-3-benzazepin-1-yl) oxy] -3-pyridinyl} -2-pyrrolidinone Chemical compound 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
Abstract
Forma de dosificacion que comprende: a) 1-{6-[(3-ciclobutil-2,3,4,5-tetrahidro-1H-3-benzazepin-7-il)oxi]-3-piridinil}-2-pirrolidinona o una de sus sales farmacéuticamente aceptables; b) un estabilizador, que reduce la degradacion de 1-{6-([3-ciclobutil-2,3,4,5-tetrahidro-1H-3-benzazepin-7-iI)oxi]-3- piridinil}-2-pirrolidinona en la forma de dosificacion cuando se compara con una forma de dosificacion que carece de dicho estabilizador; y c) un excipiente farmacéuticamente aceptable.Método para producirla y su uso para preparar un medicamento util para el tratamiento de trastornos neurologicos y psiquiátricos. Solucion o suspension que comprende dichos componentes. Reivindicacion 2: Una forma de dosificacion segun lareivindicacion 1, caracterizada porque comprende un comprimido de transporte, cuyo comprimido de transporte está recubierto al menos parcialmente por una película que comprende: a) 1-{6-[(3-ciclobutil-2,3,4,5-tetrahidro-1H-3-benzazepin-1-il)oxi]-3-piridinil}-2-pirrolidinona o una de sus sales farmacéuticamente aceptables; y b) un estabilizador, que reduce la degradacion de 1-{6-[(3-ciclobutil-2,3,4,5-tetrahidro-1H-3-benzazepin-7-il)oxi]-3-piridinil}-2-pirrolidinona en la forma de dosificacioncuando se compara con una forma de dosificacion que carece de dicho estabilizador. Reivindicacion 6: Una forma de dosificacion segun la reivindicacion 2, caracterizada porque dicho estabilizador es ácido cítrico, y en el que la relacion molar debase libre a ácido cítrico está entre 1,5:1 a 1: 500.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89226707P | 2007-03-01 | 2007-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065529A1 true AR065529A1 (es) | 2009-06-10 |
Family
ID=39248198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100842A AR065529A1 (es) | 2007-03-01 | 2008-02-28 | Forma de dosificacion que comprende 1-{6-((3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi)-3-piridinil}-2-pirrolidinona , metodo para producirla su uso para preparar un medicamento y disolucion o suspension correspondiente |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20110014283A1 (es) |
| EP (1) | EP2131818B1 (es) |
| JP (2) | JP5743177B2 (es) |
| KR (1) | KR101504371B1 (es) |
| CN (1) | CN101674806B (es) |
| AR (1) | AR065529A1 (es) |
| AU (1) | AU2008220795B2 (es) |
| BR (1) | BRPI0807882A2 (es) |
| CA (1) | CA2679529A1 (es) |
| CL (1) | CL2008000596A1 (es) |
| CO (1) | CO6220900A2 (es) |
| CR (1) | CR11013A (es) |
| DK (1) | DK2131818T3 (es) |
| DO (1) | DOP2009000207A (es) |
| EA (1) | EA019865B1 (es) |
| ES (1) | ES2463468T3 (es) |
| HK (1) | HK1137363A1 (es) |
| HR (1) | HRP20140390T1 (es) |
| IL (1) | IL200619A (es) |
| MA (1) | MA31198B1 (es) |
| MX (1) | MX2009009362A (es) |
| NZ (1) | NZ579374A (es) |
| PE (1) | PE20090114A1 (es) |
| PL (1) | PL2131818T3 (es) |
| PT (1) | PT2131818E (es) |
| SI (1) | SI2131818T1 (es) |
| TW (1) | TWI424856B (es) |
| UA (1) | UA102515C2 (es) |
| WO (1) | WO2008104590A2 (es) |
| ZA (1) | ZA200905866B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2049472B1 (en) | 2006-06-23 | 2015-01-21 | AbbVie Bahamas Ltd. | Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| WO2010023170A1 (en) * | 2008-08-29 | 2010-03-04 | Glaxo Group Limited | Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof |
| US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| JP6612874B2 (ja) | 2014-12-16 | 2019-11-27 | アクソファント サイエンシーズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006461A1 (en) * | 1993-09-03 | 1995-03-09 | Smithkline Beecham Corporation | Stabilized tablet formulation |
| ES2257886T3 (es) * | 1998-12-01 | 2006-08-01 | Dr. Reddy's Research Foundation | Nueva composicion farmaceutica y el proceso para su preparacion. |
| US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
| CA2509413C (en) * | 2002-12-20 | 2012-05-01 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
| WO2005003096A1 (en) * | 2003-06-17 | 2005-01-13 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| US20070021391A1 (en) * | 2003-06-30 | 2007-01-25 | Takayuki Doi | Preventive/remedy for urinary disturbance |
| US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| US20060002986A1 (en) * | 2004-06-09 | 2006-01-05 | Smithkline Beecham Corporation | Pharmaceutical product |
| WO2005123723A1 (en) | 2004-06-18 | 2005-12-29 | Glaxo Group Limited | 3-cycloalkylbenzazepines as histamine h3 antagonists |
| JP2006022039A (ja) * | 2004-07-08 | 2006-01-26 | Towa Yakuhin Kk | 高い安定性を有するシンバスタチン固形製剤 |
| GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
-
2008
- 2008-02-27 CL CL200800596A patent/CL2008000596A1/es unknown
- 2008-02-28 WO PCT/EP2008/052430 patent/WO2008104590A2/en active Application Filing
- 2008-02-28 PT PT87172219T patent/PT2131818E/pt unknown
- 2008-02-28 SI SI200831205T patent/SI2131818T1/sl unknown
- 2008-02-28 AU AU2008220795A patent/AU2008220795B2/en not_active Ceased
- 2008-02-28 BR BRPI0807882-3A2A patent/BRPI0807882A2/pt not_active IP Right Cessation
- 2008-02-28 JP JP2009551216A patent/JP5743177B2/ja not_active Expired - Fee Related
- 2008-02-28 CA CA002679529A patent/CA2679529A1/en not_active Abandoned
- 2008-02-28 PE PE2008000398A patent/PE20090114A1/es not_active Application Discontinuation
- 2008-02-28 US US12/528,492 patent/US20110014283A1/en not_active Abandoned
- 2008-02-28 EA EA200970817A patent/EA019865B1/ru not_active IP Right Cessation
- 2008-02-28 AR ARP080100842A patent/AR065529A1/es unknown
- 2008-02-28 UA UAA200909976A patent/UA102515C2/ru unknown
- 2008-02-28 KR KR1020097020444A patent/KR101504371B1/ko not_active IP Right Cessation
- 2008-02-28 PL PL08717221T patent/PL2131818T3/pl unknown
- 2008-02-28 CN CN2008800144640A patent/CN101674806B/zh not_active Expired - Fee Related
- 2008-02-28 DK DK08717221.9T patent/DK2131818T3/da active
- 2008-02-28 MX MX2009009362A patent/MX2009009362A/es active IP Right Grant
- 2008-02-28 NZ NZ579374A patent/NZ579374A/en not_active IP Right Cessation
- 2008-02-28 ES ES08717221.9T patent/ES2463468T3/es active Active
- 2008-02-28 EP EP08717221.9A patent/EP2131818B1/en not_active Not-in-force
- 2008-02-29 TW TW097106936A patent/TWI424856B/zh not_active IP Right Cessation
-
2009
- 2009-08-24 ZA ZA200905866A patent/ZA200905866B/xx unknown
- 2009-08-27 IL IL200619A patent/IL200619A/en not_active IP Right Cessation
- 2009-08-28 DO DO2009000207A patent/DOP2009000207A/es unknown
- 2009-08-31 MA MA32184A patent/MA31198B1/fr unknown
- 2009-09-02 CR CR11013A patent/CR11013A/es unknown
- 2009-09-10 CO CO09097361A patent/CO6220900A2/es not_active Application Discontinuation
-
2010
- 2010-05-20 HK HK10104983.9A patent/HK1137363A1/xx not_active IP Right Cessation
-
2014
- 2014-04-29 HR HRP20140390AT patent/HRP20140390T1/hr unknown
- 2014-09-19 JP JP2014191832A patent/JP2015038098A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065529A1 (es) | Forma de dosificacion que comprende 1-{6-((3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi)-3-piridinil}-2-pirrolidinona , metodo para producirla su uso para preparar un medicamento y disolucion o suspension correspondiente | |
| ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
| AR062760A1 (es) | Administracion de inhibidores de dipeptidilpetidasa | |
| GT200600496A (es) | Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea. | |
| CL2013002227A1 (es) | Sales de acido de (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, util en el tratamiento de enfermedades del snc. (divisional de la sol. 2271-08). | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| ECSP056240A (es) | Derivados de pirido[2,1-a]isoquinolina como inhibidores de dpp-iv | |
| BR0207726A (pt) | Sais farmacêuticos | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| AR036813A1 (es) | Composiciones farmaceuticas | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| SG162744A1 (en) | Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| JP2010520174A5 (es) | ||
| BR112014009242A8 (pt) | nanossuspensão farmacêutica | |
| GT200900236A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopopril-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden esta formas.- | |
| CL2008002025A1 (es) | Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. | |
| IN2012DN00977A (es) | ||
| BRPI0512151A (pt) | solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol | |
| PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
| AR077846A1 (es) | Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |